Literature DB >> 7549224

Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta 2-selective sympathomimetics.

L Mazzoni1, R Naef, I D Chapman, J Morley.   

Abstract

Allergic bronchospasm in sensitized guinea-pigs was totally suppressed by acute subcutaneous infusion of rac-salbutamol (0.69 microgram/kg per min) for < 1 h. More prolonged infusion of rac-salbutamol induced a progressive susceptibility to inhaled antigen so that, by 48 h, animals collapsed and died following inhalation of antigen. In anaesthetized animals, acute infusion of rac-salbutamol (1.67 micrograms/kg per min) suppressed airway obstruction, an effect that can be attributed to beta 2-adrenoceptor activation by the eutomer (R-salbutamol). Acute intravenous infusion of the distomer (S-salbutamol) (1.67 micrograms/kg per min) induced hyperresponsiveness to histamine without having any effect upon airway calibre. It is suggested therefore that subcutaneous infusion of rac-salbutamol initially abrogates the bronchoconstrictor response to antigen because the bronchodilator action of the eutomer predominates over hyperreactivity attributable to the distomer. Conversion from protection to susceptibility was not determined by reduced beta 2-adrenoceptor activation since animals could be protected from a lethal response to antigen by inhalation of rac-isoprenaline or by subcutaneous injection of rac-salbutamol. The seeming progressive loss of efficacy of R-salbutamol may result from disproportionate accumulation of S-salbutamol if, as in man, there is stereospecific metabolism of R-salbutamol. The capacity of S-salbutamol to evoke hyperresponsiveness is shared by S-isoprenaline and S-terbutaline and, as has been shown previously for rac-isoprenaline, the capacity of S-salbutamol to elicit hyperresponsiveness was not evidenced following section of the vagus nerves. No mechanism has yet been established which might account for this property of S-salbutamol or for other S-enantiomers of sympathomimetics.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7549224     DOI: 10.1006/pulp.1994.1043

Source DB:  PubMed          Journal:  Pulm Pharmacol        ISSN: 0952-0600


  21 in total

Review 1.  Management of acute pediatric asthma.

Authors:  John C Carl; Carolyn M Kercsmar
Journal:  Curr Allergy Asthma Rep       Date:  2002-11       Impact factor: 4.806

2.  Effects of (r,r)- and (r,r/s,s)-formoterol on airway relaxation and contraction in an experimental rat model.

Authors:  Maroun J Mhanna; Jeffrey F Koester; Robert C Cohn
Journal:  Curr Ther Res Clin Exp       Date:  2007-07

3.  Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison with Levalbuterol in Healthy Adult Volunteers.

Authors:  Manpreet K Virk; Justin Hotz; Robinder G Khemani; Christopher J L Newth; Patrick A Ross
Journal:  Lung       Date:  2017-02-16       Impact factor: 2.584

Review 4.  Anomalous effects of albuterol and other sympathomimetics in the guinea pig.

Authors:  J Morley
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

5.  Concerns regarding the current use of beta-agonists in the therapy of asthma.

Authors:  G Aberg; J Costello
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

6.  Differential responses of asthmatic airways to enantiomers of albuterol. Implications for clinical treatment of asthma.

Authors:  M Perrin-Fayolle; P S Blum; J Morley; M Grosclaude; M T Chambe
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

Review 7.  The pharmacokinetics of levosalbutamol: what are the clinical implications?

Authors:  D W Boulton; J P Fawcett
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

8.  Bronchopulmonary pharmacokinetics of (R)-salbutamol and (S)-salbutamol enantiomers in pulmonary epithelial lining fluid and lung tissue of horses.

Authors:  Glenn A Jacobson; Sharanne Raidal; Kate Robson; Christian K Narkowicz; David S Nichols; E Haydn Walters
Journal:  Br J Clin Pharmacol       Date:  2017-02-08       Impact factor: 4.335

9.  Levosalbutamol vs racemic salbutamol in the treatment of acute exacerbation of asthma.

Authors:  Ajay Punj; Ashish Prakash; Ashu Bhasin
Journal:  Indian J Pediatr       Date:  2009-11       Impact factor: 1.967

10.  Randomized placebo controlled assessment of airway inflammation due to racemic albuterol and levalbuterol via exhaled nitric oxide testing.

Authors:  John F Freiler; Rajiv Arora; Thomas C Kelley; Larry Hagan; Patrick F Allan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.